Opinion
Video
Additional Forward-Looking Data and Studies Beyond Frontline Therapy in RCC
Author(s):
EP: 1.Treatment Selection in the Frontline Setting of Advanced Clear Cell RCC
EP: 2.Dr Wulff-Burchfield Reviews CheckMate 214 and CheckMate 9ER
EP: 3.Dr Xu Reviews Data from the CLEAR Trial and Recent Analyses at ASCO 2024 - Lenvatinib + Pembrolizumab in Frontline Advanced RCC
EP: 4.Dr Voss Shares Highlights from the COSMIC-313 and LITESPARK-024 Trials
EP: 5.Exciting Data and Trials in Progress from ASCO 2024
EP: 6.Ongoing RCC Clinical Trials that may Impact Practice
EP: 7.Dr Xu Provides Clinical Perspective on the CONTACT-03 Trial Outcomes
EP: 8.Dr Voss Application of Updated KEYNOTE-564 Data
EP: 9.Guiding Sequencing & Finding a Contemporary Regimen/ Approach to Treatment Post-Checkpoint Inhibition
EP: 10.World Health Organization (WHO) Classification Updates for Papillary RCC
Now Viewing
EP: 11.Additional Forward-Looking Data and Studies Beyond Frontline Therapy in RCC
EP: 12.The Role of Chemotherapy in nccRCC Treatment
EP: 13.Select Ongoing Trials for nccRCC and Impact on the Treatment Landscape
EP: 14.Final Thoughts/Looking Forward
1. Please mention if there are any other recently published or pending data for treatment of patients with RCC beyond frontline therapy that you are looking forward to
Related Videos
Related Content
